QI Path Unveils AI-Driven Risk Intelligence Platform for Life Sciences

QI Path has launched an AI-driven risk governance platform aimed at transforming risk mitigation and regulatory readiness across the drug development lifecycle, announced in a press release. The platform is designed to provide real-time visibility into critical areas such as inspection readiness, protocol compliance, manufacturing integrity, and clinical execution.

The platform integrates cross-functional risk data from Quality, Clinical, Regulatory, and Manufacturing teams, offering a unified view of exposure. This approach ensures that risks, deviations, change controls, and CAPAs are managed as part of a dynamic and traceable risk ecosystem, rather than isolated incidents.

QI Path's platform is proactive, mapping systemic vulnerabilities and surfacing unresolved issues before audits. It continuously updates multi-dimensional risk analysis based on real-world data, helping organizations not only survive inspections but also lead in operational excellence. This launch comes at a time when the life sciences industry faces increasing protocol complexity and demands greater transparency and inspection readiness, particularly following recent FDA guidance on AI use in drug development.